BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:AMO959 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of AMO959\, from ClinicalTrials.gov estimate
 s.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07226986-11246@assetmemo.bio
DTSTAMP:20261121T005632Z
DTSTART;VALUE=DATE:20280710
DTEND;VALUE=DATE:20280711
SUMMARY:AMO959: Phase 1/2 readout est. (NCT07226986)
DESCRIPTION:AMO959\, phase 1/2\, Prostate Cancer.\nStudy: A Phase Ib/II Ope
 n-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA61
 7) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC
 \nEstimated primary completion: 10 July 2028. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/amo959#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07226986
URL:https://assetmemo.bio/drug/amo959#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
